Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2022-05-17 Regulatory Filings
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Recording of Analysts/Institutional Investor Meet/Con. Call
Regulatory Filings Classification · 90% confidence The document is a letter addressed to stock exchanges regarding the audio recording of a conference call held on May 17, 2022, discussing Q3 results and future outlook. It mentions that the audio recording link has been uploaded and that the written transcript will be submitted later. The document does not contain the transcript itself or detailed financial data, but is an announcement about the availability of the conference call recording and forthcoming transcript. According to the classification rules, announcements about conference calls or their recordings are classified as Call Transcript (CT) if the full transcript is provided, but since this document only announces the audio recording and promises the transcript later, it is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement without the actual transcript or financial data.
2022-05-17 English
Re-appointment
Board/Management Information Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (NSE and BSE) regarding the recommendation by the Board of Directors for the re-appointment of the statutory auditors for a five-year term. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(2), which pertains to disclosures about changes in the company. The content focuses on the appointment of auditors, including their profile and term, but does not contain any financial statements or audit results. It is an announcement of a board decision related to auditors, not the audit report itself. Therefore, it fits best under 'Board/Management Information' (MANG), which covers announcements of changes in the company's board or senior management, including auditor appointments as part of governance disclosures.
2022-05-17 English
Outcome of Board Meeting
Annual Report Classification · 95% confidence The document is a detailed announcement from Indoco Remedies Limited dated May 17, 2022, reporting the outcome of a Board Meeting. It includes audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2022, along with the statutory auditor's report expressing an unmodified opinion. The document contains comprehensive financial statements including income statements, balance sheets, cash flow statements, and notes. It also mentions dividend recommendations and auditor re-appointment proposals subject to shareholder approval at the upcoming AGM. The presence of full financial data, auditor's report, and detailed financial analysis for the full fiscal year indicates this is the official Annual Report or equivalent annual financial results filing. The document is not merely an announcement of report publication or a brief earnings release; it contains substantive financial data and audit opinions. Therefore, the appropriate classification is Annual Report (10-K). FY 2022
2022-05-17 English
Dividend
Annual Report Classification · 95% confidence The document is a detailed announcement from Indoco Remedies Limited dated May 17, 2022, reporting the outcome of a Board Meeting. It includes audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2022, along with the statutory auditor's report expressing an unmodified opinion. The document contains comprehensive financial statements including income statements, balance sheets, and cash flow statements, as well as notes and auditor's opinion. It also mentions dividend recommendations and re-appointment of auditors, which are typical contents of an annual financial report. The presence of full financial data and auditor's report confirms this is the actual Annual Report or equivalent annual financial disclosure, not just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2022-05-17 English
Dividend
Annual Report Classification · 95% confidence The document is a detailed announcement from Indoco Remedies Limited dated May 17, 2022, reporting the outcome of a Board Meeting. It includes audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2022, along with the statutory auditor's report. The document contains comprehensive financial statements including income statements, balance sheets, and cash flow statements, as well as notes and auditor's opinion. It also mentions dividend recommendations and re-appointment of auditors, which are typical contents of an annual financial report. The presence of full financial data and audit opinion confirms this is the actual Annual Report filing rather than a brief announcement or certification. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2022-05-17 English
Financial Result Updates
Annual Report Classification · 95% confidence The document is a detailed announcement from Indoco Remedies Limited dated May 17, 2022, reporting the outcome of a Board Meeting. It includes audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2022, along with the statutory auditor's report expressing an unmodified opinion. The document contains comprehensive financial statements including income statements, balance sheets, and cash flow statements, as well as notes and auditor's opinion. It also mentions dividend recommendations and re-appointment of auditors, which are typical contents of an annual financial report. The presence of full financial data and auditor's report confirms this is the actual Annual Report filing rather than just an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K). FY 2022
2022-05-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.